

Akums opens new facility for lyophilised and sterile dosage manufacturing

04 January 2025 | News

Equipped with state-of-the-art technology to produce high-quality lyophilised (freeze-dried) products



Akums Drugs & Pharmaceuticals, a Delhi-based Contract development and manufacturing organization (CDMO), has announced its new state-of-the-art sterile manufacturing facility, dedicated to producing lyophilised products, in Haridwar.

In addition to lyophilised injectables, the facility is equipped to manufacture vials, ampoules, Form-Fill-Seal (FFS) products, and eye and ear drops.

The global lyophilised injectables market, estimated at a value of approximately \$3,365.4 million in 2023, is expected to experience steady growth, reaching an impressive \$4,978.3 million by 2030.

With a compound annual growth rate (CAGR) of 5.6% during the forecast period, this market demonstrates strong potential driven by increasing demand for products requiring enhanced stability and extended shelf life. As a niche segment with high entry barriers and limited competition, it presents significant opportunities to innovate and cater to specialized therapeutic needs. This growth highlights the strategic importance of investing in lyophilization capabilities.

The facility, which is now operational, is equipped with state-of-the-art technology to produce high-quality lyophilised (freeze-dried) products across various therapeutic categories. Lyophilisation is a crucial process in preserving the stability and shelf life of pharmaceutical products, especially for sensitive chemical compounds.

By entering this space, Akums aims to meet the growing global demand for these products. Akums' lyophilisation facility offers a robust production capacity and the flexibility to handle multiple vial sizes, ensuring it can cater to a broad range of healthcare needs.